Navigation Links
National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
Date:3/9/2010

Research in inflammatory bowel diseases (IBD) is changing and improving the way Crohn’s disease and ulcerative colitis—chronic and often debilitating digestive diseases impacting 1.4 million Americans—are diagnosed and treated. On Tuesday, March 30, at 1 PM ET , Crohn’s and colitis patients, families, and caregivers can tune into a Crohn’s & Colitis Foundation of America (CCFA) interactive educational webcast/teleconference entitled, “Breakthroughs in IBD Research: Helping You Today.” National expert and researcher Stephan R. Targan, MD, Director of the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai Medical Center, will discuss recent advances in IBD research and answer audience questions during an interactive question and answer session.

New York, NY (Vocus) -- Research in inflammatory bowel diseases (IBD) is changing and improving the way Crohn’s disease and ulcerative colitis—chronic and often debilitating digestive diseases impacting 1.4 million Americans—are diagnosed and treated. On Tuesday, March 30, at 1 PM ET , Crohn’s and colitis patients, families, and caregivers can tune into a Crohn’s & Colitis Foundation of America (CCFA) interactive educational webcast/teleconference entitled, “Breakthroughs in IBD Research: Helping You Today.” National expert and researcher Stephan R. Targan, MD, Director of the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai Medical Center, will discuss recent advances in IBD research and answer audience questions during an interactive question and answer session

During the program, participants will receive insight into important questions about research in inflammatory bowel diseases including:
o   What is currently going on in research, how close are we to answers?
o   How will advances in IBD genetics and immunology impact me?
o   When should an infusion or injection therapy be considered in IBD treatment?
o   What are clinical trials and how can they benefit me?

Board certified in internal medicine, gastroenterology and infectious disease, Dr. Targan has been awarded investigative grants from the National Institutes of Health (NIH), CCFA’s Scientific Achievement Award for Clinical Science, as well as research contracts with numerous industry sponsors. His research has primarily focused on the genetic and immunopathologic mechanisms of inflammatory bowel disease.

"Research into Crohn’s disease and ulcerative colitis is rapidly advancing, allowing for better therapies for patients today and tomorrow,” says Dr. Targan. “Patients are asking how Crohn’s and colitis breakthroughs are going to impact their quality of life now and down the road, and the Crohn’s & Colitis Foundation’s March 30 teleconference will help answer these questions.”

Shire is sponsoring this event. Registration is available at no cost to participants via an online portal at www.ccfa.org/webcasts/research and by phone at 1-877-547-5641 ext. 312.

About Crohn’s Disease & Ulcerative Colitis
Crohn’s disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn’s disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn’s disease or ulcerative colitis, with as many as 150,000 under the age of 18. Most people develop the diseases between the ages of 15 and 35.

About the Crohn’s & Colitis Foundation
The Crohn’s & Colitis Foundation of America’s mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 81 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau’s Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information, contact the Foundation at 800-932-2423 or visit www.ccfa.org. Join CCFA on Facebook at http://apps.facebook.com/supportccfa/ and follow CCFA on Twitter at www.twitter.com/ccfa.

SHIRE PLC
Shire is a leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician, and focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases. For further information on Shire, visit http://www.shire.com.

Media Contact:
Ariella Levine
1-646-943-7430
alevine(at)ccfa(dot)org

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3705294.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. $250,000 Bioactive Beverage Challenge Announced By Tahitian Noni International
2. Latex Mattress Retailer Celebrates National Sleep Awareness Week with Pledge to Help Women and Kids in Shelters Sleep Better
3. Quantros Releases Video in Recognition of National Patient Safety Week
4. Diet and Healthy Weight Tips for National Nutrition Month from Patients Medical
5. National Prosthodontics Awareness Week Serves and Educates Consumers About Proper Oral Health Care
6. March is National Professional Social Work Month
7. St. Elizabeth Medical Residents to Present Research at International Meeting
8. National Climate Organizations Join Forces In Historic Push For Climate and Clean Energy Solutions
9. Blue Cross and Blue Shield Companies To Host Fourth Annual National Walk@Lunch Day(R) on April 28, 2010
10. Natures Peak Products Along With Company President Paul Wilkinson Were Recently Featured on Segment of Lifetime TV Networks Nationally Broadcast Show The Balancing Act
11. Christiana Care Health System Wins National Award for Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its site, ... matching users with high quality water pipes within an ideal price range. The site ... was founded by two brothers, Nick and Mike Hunter, who use medical cannabis to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: